Psilocybin Treatment for Treatment-Resistant Depression

Warning: count(): Parameter must be an array or an object that implements Countable in /home/modymeuk/ukmusha.co.uk/system/library/template/Twig/Extension/Core.php on line 1266Warning: count(): Parameter must be an array or an object that implements Countable in /home/modymeuk/ukmusha.co.uk/system/library/template/Twig/Extension/Core.php on line 1266

Oxford Health NHS Foundation Trust has launched the COMP006 study, an international clinical trial investigating the efficacy, safety, and tolerability of COMP360 psilocybin for individuals with treatment-resistant depression (TRD). TRD refers to depression that persists despite treatment with at least two antidepressant medications. Psilocybin, a psychedelic compound that occurs naturally in magic mushrooms, interacts with the brain's serotonin system, influencing mood, sleep, and cognition.

In this study, a synthetic form of psilocybin, COMP360, is administered alongside psychological support from trained therapists. Early trial phases have shown promising results, with a single 25mg dose leading to significant reductions in depressive symptoms for up to 12 weeks. The study is being conducted at the NIHR Oxford Health Clinical Research Facility, located at the Warneford Hospital in Oxford. Participants will attend several study visits, each lasting up to eight hours, and will be reimbursed for reasonable travel and other out-of-pocket expenses. To be eligible, individuals must live within a 50-mile radius of Oxford.

For more information from the NHS about the study or participation, please see their article: New Study on Psilocybin Treatment for Treatment-Resistant Depression

You may also visit the COMP006 Study: Exploring potential new routes away from treatment-resistant depression directly where you may also express an interest in participating.

---